compare abundances of cell clusters, the association model Prediction Analysis for Microarrays (PAMR) was applied with a minimum cluster size of 2.2%, 5 cross-validation folds and a false discovery rate of 1%. Results: Conventional biaxial gating showed that there were large differences in the proportions of both IFNγ + CD4 T cells (1-15%) and IL-17A + CD4 T cells (0-9%) within and between RA and HC. The proportion of IFNγ + CD4 T cells (Th1) did not correlate with that of IL-17A + T cells (Th17), leading to the generation of 4 immunophenotypes: "Th1", "Th17", "double-hi", and "low", determined by cytokine expression. Using CITRUS we identified 3 clusters of cells which differed significantly in abundance between HC and RA. Cluster 1 was CD4 + CD38 + , had characteristics of regulatory T cells and was more abundant in HC. Cluster 2 was CD28 low CD8 + expressing perforin and Tbet, and cluster 3 a CD127 high CCR6 + population, both of which were more abundant in RA. Conclusions: Cytokine expression of ex vivo stimulated T cells from RA and HC is highly variable and can be detected using mass cytometry. Cytokine signatures of this kind may be informative when predicting treatment response. CITRUS identified 3 cell clusters which may have been missed using conventional methods of analysis. Importantly, CITRUS allowed inspection of the phenotype of each cluster. Our next step is to compare RA responders to non-responders using the methods described. The function of these clusters will be further investigated by cell isolation with fluorescence-activated cell sorting (FACS) and may go some way in predicting treatment response. Finally we recommend the use of both automated clustering algorithms alongside conventional gating methods when analysing high-dimensional data. Background: A period of ANA positivity and other immune dysregulation precedes connective tissue disease, providing a potential opportunity for disease prevention. Type I interferons (IFN-I) play a role in pathogenesis but their role in disease initiation is unclear. Objectives: To develop biomarkers of progression to systemic autoimmunity, with a view to enabling early intervention for disease prevention. Methods: A prospective observational study was conducted in 125 patients At Risk of CTD defined by (i) ANA; (ii) ≤1 clinical SLE criteria; (iii) symptom duration <12 months and (iv) treatment-naïve. Progression was defined by meeting 2012 ACR/SLICC SLE, 2016 ACR/EULAR Primary Sjogren's, or other diagnostic criteria. Expression of 30 selected="selected" ISGs was measured using Taqman. Factor analysis was used to reduce the gene expression data to a limited set of factors, which were compared between patient groups using Mann Whitney U Test. Two factor scores explained 80% of the data variance; "Score A" (composed of IFN-α responsive genes) and "Score B" (genes responsive to IFN-α and γ). 95 healthy controls and 107 SLE patients were used as negative and positive controls. Results: 82 patients with 1-year follow-up data were studied. 71 were female with mean age 48±15 years. 16 (20%) patients progressed to CTD (SLE=12, Sjogren's=4) in the following 12 months. At baseline, only IFN Score A was increased in both At Risk-CTD and SLE vs healthy controls; p<0.001. IFN Score B was only increased in true established SLE. In At-Risk patients, IFN Score B was low in patients who did not progress and increased in those who did progress; p=0.004. However, there was no difference in IFN Score A between these two groups; p=0.252 (Figure 1 ). Although complement levels and lymphocyte counts were lower in SLE, these were not different between the At-Risk progression and non-progression groups. Anti-dsDNA titres were higher in SLE but not different between the progression groups; all p>0.10. (Figure 1 ). Other genes such as those encoding ECM production related proteins, genes associated with posttranslational methylation, and genes for numerous chemokines and cytokines were also differentially overexpressed in SSc EC. Increased gene expression and increased protein levels of selected ISGs were confirmed by Western blots. 
Conclusions

Methods:
In whole blood of 50 pSS patients modular IFN scores were determined using real-time quantitative PCR followed by principal component analysis. Subsequently, five indicator genes per module were analysed in two independent European cohorts with a total of 141 patients. Results: Three groups were distinguished: without IFN activation (19-47%), with IFN type I (53-81%) and with IFN type I+II activation (35-55%). Patients with IFN activation (I or I+II) have a higher presence of auto-antibodies, IgG levels and lower lymphocyte counts compared to IFN negative patients. The biological domain of the EULAR Sjögren's Syndrome Disease Activity Index (biological-ESSDAI) was higher in patients with IFN activation, while total-ESSDAI scores were not significantly different. 66-67% of the IFN type I positive patients had an additional IFN type II inducible gene expression. Patients with IFN type I+II activation have significantly higher IgG levels and lower lymphocyte counts compared to patients with only IFN type I activation. There were no differences in fatigue or dryness, but pain scores were lower. Conclusions: pSS patients can be stratified according to their systemic IFN activation patterns. IFN activation (I or I+II) is present in patients with the highest activity of the biological-ESSDAI. These data raise the possibility that the biological-ESSDAI rather than total-ESSDAI score may be a more sensitive endpoint for trials targeting either type I or type II IFN pathways. Background: Vobarilizumab is a Nanobody ® consisting of an anti-IL-6R domain and an anti-human serum albumin domain in development for treatment of RA. The efficacy and safety were assessed in a 24-week double-blind global phase 2b study in patients with active RA on a stable background of MTX. Main efficacy and safety results were previously reported [1] . Objectives: To report the impact of treatment with vobarilizumab on secondary efficacy endpoints including SDAI and CDAI remission and the sustained response at 4 consecutive visits based on ACR50, ACR70 and DAS28 CRP . Methods: Patients were randomized to receive subcutaneously administered placebo or 1 of 4 dose regimens of vobarilizumab in addition to MTX. SDAI and CDAI remission at Week 24 was evaluated, as was maintenance of efficacy as defined by sustained DAS28 CRP <2.6 responses at 4 consecutive visits (i.e., at Weeks 12, 16, 20 and 24) . In addition, a post-hoc analysis was performed on sustained ACR50 and ACR70 responses from Week 12 through Week 24. Proportions of patients achieving response for these endpoints were summarized by treatment group. Subjects with missing values were analyzed as non-responders. Results: A total of 345 patients were randomized. Demographics and baseline characteristics were similar across groups with mean baseline DAS28 CRP between 5.8 and 6.2. At Week 24, up to 19% and 20% in the vobarilizumab groups reached CDAI and SDAI remission, respectively vs. 10% and 9% who received placebo (Table 1) . At Week 24, up to 61% and 45% of the patients in the vobarilizumab groups achieved an ACR50 or ACR70 response, respectively (39% and 17% on placebo). Approximately one third of the randomized patients in the 3 highest treatment groups had a sustained ACR50 response from Week 12 through Week 24 (Table  2 ). Sustained remission defined by DAS28 CRP <2.6 at 4 consecutive visits, i.e. at weeks 12, 16, 20 and 24, was observed in 20% to 25% of the patients in the 3 highest dosing arms compared with 3% of those receiving placebo. Conclusions: In patients with active RA, treatment with vobarilizumab at the 3 highest dose regimens in addition to MTX had a positive and sustained impact on disease activity through Week 24 as defined by clinically relevant efficacy endpoints. 
